TipRanks
Oculis Holding (OCS)
NASDAQ:OCS
US Market
OCS
Oculis Holding
RESEARCH TOOLSreports
Want to see OCS full AI Analyst Report?

Oculis Holding (OCS) Stock News & Sentiment

224 Followers
Oculis: Precision-Medicine Pipeline Progress Supports Reiterated Buy Rating and Unchanged $39 Price Target
Premium
Ratings
Oculis: Precision-Medicine Pipeline Progress Supports Reiterated Buy Rating and Unchanged $39 Price Target
11d ago
OCS
Oculis Holding Announces Board Resignation of Long-Serving Director Lionel Carnot
Premium
Company Announcements
Oculis Holding Announces Board Resignation of Long-Serving Director Lionel Carnot
1M ago
6K
OCS
Oculis: Advancing Privosegtor in Optic Neuritis and MS Relapses Supports Buy Rating and Unchanged $26 Price Target
Premium
Ratings
Oculis: Advancing Privosegtor in Optic Neuritis and MS Relapses Supports Buy Rating and Unchanged $26 Price Target
2M ago
OCS
Oculis to Acquire Full Rights to Privosegtor in Asset Deal with Accure Therapeutics
Premium
Company Announcements
Oculis to Acquire Full Rights to Privosegtor in Asset Deal with Accure Therapeutics
3M ago
6K
OCS
Oculis Holding Reports Strong Equity Base and Updates SEC Risk Factors in Q2 2026 Filing
Premium
Company Announcements
Oculis Holding Reports Strong Equity Base and Updates SEC Risk Factors in Q2 2026 Filing
3M ago
6K
OCS
Oculis: Privosegtor’s Pivotal MS Opportunity and FDA Alignment Underpin Unchanged $45 Price Target and Buy Rating
Premium
Ratings
Oculis: Privosegtor’s Pivotal MS Opportunity and FDA Alignment Underpin Unchanged $45 Price Target and Buy Rating
3M ago
OCS
Oculis Advances Privosegtor Into Phase 3 Optic Neuritis Trial: What Investors Should Watch
Premium
Company Announcements
Oculis Advances Privosegtor Into Phase 3 Optic Neuritis Trial: What Investors Should Watch
4M ago
OCS
More OCS News >

OCS News on the Web

Oculis To Present Additional Phase 2 ACUITY Biomarker Data For Privosegtor In Optic Neuritis
rttnews
Bullish
Weekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals
rttnews
Bullish
J.P. Morgan Gives a Buy Rating to Oculis Holding (OCS)
TipRanks News
Bullish
Oculis Holding (OCS) Acquires Global Rights to Privosegtor and ACT-02 in $3.8M Deal
GuruFocus News
Bullish
Oculis Updates Investor Presentation, Emphasizing Late-Stage Neuro-Ophthalmic Pipeline and Cash Runway
TipRanks News
Neutral
Analysts Have Conflicting Sentiments on These Healthcare Companies: Autolus Therapeutics (AUTL), Galmed Pharmaceuticals (GLMD) and Oculis Holding (OCS)
TipRanks News
Bullish
Oculis Holding AG at Goldman Sachs Healthcare Conference Transcript
GuruFocus News
Neutral
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
The Motley Fool
Bearish

News Score - Last 7 Days

Neutral
OCS
Sector Average
Media Buzz
This Week1 articles
Weekly Average2 articles
News Sentiment
This Week50%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is OCS’s Media Buzz Sentiment?
1 articles about OCS were published this week. In an average week, 2 articles are published.
    What is OCS’s weekly average amount of articles?
    In an average week, 2 articles about OCS are published.
      What is OCS’s News Sentiment?
      50% of articles about OCS were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        CNCCentene
        GMABGenmab
        LHLabcorp Holdings
        KIDSOrthoPediatrics
        DXCMDexcom
        Showing the stocks with the most bullish news sentiment over the past week